DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · IEX Real-Time Price · USD
2.490
-0.110 (-4.23%)
At close: Apr 18, 2024, 4:00 PM
2.450
-0.040 (-1.61%)
After-hours: Apr 18, 2024, 4:00 PM EDT

DiaMedica Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Revenue
000000.500
Gross Profit
000000.500
Selling, General & Admin
8.166.164.884.493.692.741.310.6
Research & Development
13.117.848.778.217.94.523.211.73
Operating Expenses
21.271413.6512.711.597.264.522.33
Operating Income
-21.27-14-13.65-12.7-11.59-6.76-4.52-2.33
Other Expense / Income
-2.01-0.33-0.03-0.43-0.98-1.11-0.26-0.11
Pretax Income
-19.26-13.67-13.61-12.27-10.62-5.65-4.26-2.22
Income Tax
0.040.030.030.030.030.0800
Net Income
-19.3-13.7-13.64-12.3-10.65-5.73-4.26-2.22
Shares Outstanding (Basic)
3326211612865
Shares Outstanding (Diluted)
3326211612865
Shares Change
23.16%27.29%32.48%30.80%54.81%30.45%25.34%-
EPS (Basic)
-0.60-0.52-0.65-0.78-0.89-0.74-0.72-0.47
EPS (Diluted)
-0.60-0.52-0.65-0.78-0.89-0.74-0.72-0.47
Free Cash Flow
-18.75-11.59-12.27-9.22-9.09-5.75-3.92-2.99
Free Cash Flow Per Share
-0.58-0.44-0.59-0.59-0.76-0.74-0.66-0.63
Gross Margin
-----100.00%--
Operating Margin
------1352.20%--
Profit Margin
------1146.80%--
Free Cash Flow Margin
------1149.20%--
EBITDA
-19.16-13.58-13.53-12.2-10.55-5.64-4.26-2.22
EBITDA Margin
------1127.80%--
Depreciation & Amortization
0.10.090.080.070.070.0200
EBIT
-19.26-13.67-13.61-12.27-10.62-5.65-4.26-2.22
EBIT Margin
------1130.80%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).